ATE477799T1 - Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung - Google Patents

Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung

Info

Publication number
ATE477799T1
ATE477799T1 AT06709121T AT06709121T ATE477799T1 AT E477799 T1 ATE477799 T1 AT E477799T1 AT 06709121 T AT06709121 T AT 06709121T AT 06709121 T AT06709121 T AT 06709121T AT E477799 T1 ATE477799 T1 AT E477799T1
Authority
AT
Austria
Prior art keywords
production
compositions containing
containing same
substituted pyrazolopyridines
pyrazolopyridines
Prior art date
Application number
AT06709121T
Other languages
English (en)
Inventor
Baptiste Ronan
Michel Tabart
Frank Halley
Eric Bacque
Catherine Souaille
Antonio Ugolini
Fabrice Viviani
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36593766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE477799(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0500555A external-priority patent/FR2880891B1/fr
Priority claimed from FR0507505A external-priority patent/FR2888579A1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE477799T1 publication Critical patent/ATE477799T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06709121T 2005-01-19 2006-01-18 Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung ATE477799T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0500555A FR2880891B1 (fr) 2005-01-19 2005-01-19 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
FR0507505A FR2888579A1 (fr) 2005-07-13 2005-07-13 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
PCT/FR2006/000114 WO2006077319A1 (fr) 2005-01-19 2006-01-18 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
ATE477799T1 true ATE477799T1 (de) 2010-09-15

Family

ID=36593766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06709121T ATE477799T1 (de) 2005-01-19 2006-01-18 Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung

Country Status (24)

Country Link
US (2) US8008322B2 (de)
EP (1) EP1845978B1 (de)
JP (1) JP2008527025A (de)
KR (1) KR20070098923A (de)
AR (1) AR052357A1 (de)
AT (1) ATE477799T1 (de)
AU (1) AU2006207442A1 (de)
BR (1) BRPI0606504A2 (de)
CA (1) CA2595041A1 (de)
CY (1) CY1110926T1 (de)
DE (1) DE602006016233D1 (de)
DK (1) DK1845978T3 (de)
HR (1) HRP20100624T8 (de)
IL (1) IL184524A0 (de)
MX (1) MX2007008790A (de)
PA (1) PA8660301A1 (de)
PE (1) PE20061119A1 (de)
PL (1) PL1845978T3 (de)
PT (1) PT1845978E (de)
RU (1) RU2375360C2 (de)
SI (1) SI1845978T1 (de)
TW (1) TW200639173A (de)
UY (1) UY29341A1 (de)
WO (1) WO2006077319A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870410A1 (de) * 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Arylpyrazolopyridine und ihre Salze, diese enthaltende pharmazeutische Zubereitungen, verfahren zu ihrer Herstellung und ihre Verwendung
EP2042500A1 (de) * 2007-09-21 2009-04-01 Bayer Schering Pharma Aktiengesellschaft N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-Harnstoff-Verbindungen deren pharmazeutische Zusammensetzungen, Verfahren zu deren Herstellung und Verwendungen als Tie2-Kinase Hemmer
EP1932845A1 (de) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-Pyrazolopyridine und Salze davon, diese enthaltende pharmazeutische Zusammensetzungen , Verfahren zur ihrer Herstellung und ihre Verwendung
US20090062273A1 (en) * 2006-12-15 2009-03-05 Ingo Hartung 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same.
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8173635B2 (en) * 2007-11-02 2012-05-08 Vertex Pharmaceuticals Incorporated Kinase inhibitors
EP2070929A1 (de) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylarylverbindungen und Salze davon, pharmazeutische Zusammensetzungen damit sowie Verfahren zu ihrer Herstellung und Verwendung
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
EP2242757B1 (de) 2008-01-09 2012-08-01 Array Biopharma, Inc. Pyrazolopyridine als kinaseinhibitoren
WO2009114870A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2408772B1 (de) * 2009-03-19 2015-07-01 Medical Research Council Technology Verbindungen
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JP2013542259A (ja) 2010-11-12 2013-11-21 ブリストル−マイヤーズ スクイブ カンパニー 置換アザインダゾール化合物
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US20140161720A1 (en) * 2011-05-26 2014-06-12 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
US9260425B2 (en) * 2011-08-12 2016-02-16 Genetech, Inc. Pyrazolo[3,4-c]pyridine compounds and methods of use
EP2818473A4 (de) 2012-02-20 2015-04-15 Takeda Pharmaceutical Heterocyclische verbindung
CA2882950A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
DK2940014T3 (en) 2012-12-28 2018-12-10 Crystalgenomics Inc 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
CN103524421B (zh) * 2013-09-29 2015-04-01 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用
EP3774797B1 (de) 2018-04-05 2025-11-19 Merck Patent GmbH Heteroarylverbindungen als typ-ii-irak-inhibitoren und verwendungen davon
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP2025501767A (ja) 2021-12-22 2025-01-23 アナシス・ファルマ・プロプライエタリー・リミテッド アリールスルホンアミド化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1182896B (de) * 1963-04-02 1964-12-03 Merck Ag E Fungizide Mittel
HK1053831A1 (zh) 1999-09-17 2003-11-07 Basf Aktiengesellschaft 作为治疗药物的激酶抑制剂
MXPA03000436A (es) * 2000-07-18 2003-06-24 Yamanouchi Pharma Co Ltd Medicamentos que compreden derivados de dicianopiridina.
CA2416527C (en) * 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
FR2827603B1 (fr) 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
EP1534389A2 (de) * 2002-07-23 2005-06-01 SmithKline Beecham Corporation Pyrazolopyrimidine als kinaseinhibitoren
US7186716B2 (en) * 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
UA81453C2 (en) * 2003-02-27 2008-01-10 Pyrazolopyridine derivates
AU2004233827B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
KR100976076B1 (ko) * 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP2005325099A (ja) * 2004-04-12 2005-11-24 Sankyo Co Ltd チエノピリジン誘導体
MXPA06013250A (es) * 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
ATE554087T1 (de) * 2004-10-29 2012-05-15 Abbott Lab Neue kinaseinhibitoren
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
EP1683796A1 (de) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridine, ihre Herstellung und ihre medizinische Verwendung
AU2006223409B2 (en) 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007056582A1 (en) 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
TW200815437A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870410A1 (de) * 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Arylpyrazolopyridine und ihre Salze, diese enthaltende pharmazeutische Zubereitungen, verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
EP1845978A1 (de) 2007-10-24
JP2008527025A (ja) 2008-07-24
AU2006207442A1 (en) 2006-07-27
HRP20100624T1 (hr) 2010-12-31
EP1845978B1 (de) 2010-08-18
WO2006077319A1 (fr) 2006-07-27
MX2007008790A (es) 2007-09-11
RU2375360C2 (ru) 2009-12-10
RU2007131274A (ru) 2009-02-27
HRP20100624T8 (hr) 2011-01-31
SI1845978T1 (sl) 2010-12-31
UY29341A1 (es) 2006-08-31
KR20070098923A (ko) 2007-10-05
US20110190337A1 (en) 2011-08-04
CA2595041A1 (fr) 2006-07-27
PA8660301A1 (es) 2006-09-08
PT1845978E (pt) 2010-11-29
DK1845978T3 (da) 2010-12-13
PE20061119A1 (es) 2006-11-27
US8008322B2 (en) 2011-08-30
IL184524A0 (en) 2007-10-31
CY1110926T1 (el) 2015-06-10
TW200639173A (en) 2006-11-16
DE602006016233D1 (de) 2010-09-30
PL1845978T3 (pl) 2011-02-28
BRPI0606504A2 (pt) 2009-06-30
US20080039491A1 (en) 2008-02-14
AR052357A1 (es) 2007-03-14

Similar Documents

Publication Publication Date Title
ATE433976T1 (de) Substituierte pyrrolopyridine, zusammensetzungen damit und verfahren zu ihrer herstellung und verwendung
EP1919703A4 (de) Verbundwerkstoffe mit modulierter zusammensetzung und verfahren zu deren herstellung
EP2084249A4 (de) Brennstoffzusammensetzungen mit farnesan und farnesanderivaten sowie verfahren zu ihrer herstellung und verwendung
DE602005007419D1 (de) Rohmix-pulverzusammensetzungen und verfahren zu deren herstellung
DE602006020386D1 (de) Duraimplantat und Verfahren zu seiner Herstellung
EP1800317A4 (de) Isolatorbeschichtung und verfahren zu ihrer herstellung
DE602006012666D1 (de) Ren eignen und verfahren zu deren herstellung
ATE419260T1 (de) C-aryl-glucosid-sglt2-inhibitoren und verfahren zu ihrer herstellung
ATE556077T1 (de) Tetrahydrochinolinderivate und verfahren zu deren herstellung
EP1921674A4 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE602006016233D1 (de) Substituierte pyrazolopyridine, diese enthaltende sowie deren verwendung
DE602004015907D1 (de) Konjugierte Dienamide, Verfahren zur deren Herstellung, diese enthaltende Zusammensetzungen sowie deren Verwendung
ATE460401T1 (de) 1,2,4,5-tetrahydro-3h-benzazepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
EP2350013A4 (de) Zusammensetzungen zur markierung und identifizierung von autophagosomen sowie verfahren zu ihrer herstellung und verwendung
ATE526307T1 (de) Hydroxybiphenyl-carbonsäuren und derivate, verfahren zu deren herstellung und deren verwendung
EP1906468A4 (de) Batteriedose und verfahren zu ihrer herstellung
DE602005023199D1 (de) Darreichungsformen mit mikroreliefoberfläche sowie verfahren und vorrichtung für deren herstellung
DE502006005961D1 (de) Endoskop und Verfahren zu seiner Herstellung
DE602006013001D1 (de) Zusammensetzung mit verbesserter stabilität und verfahren zu ihrer herstellung
ATE535510T1 (de) Benzylamine, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmende mittel
ATE517092T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
ATE462408T1 (de) Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
DE602005018911D1 (de) 1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen
DE112005003550A5 (de) Flüssige Bio-Brennstoffmischung sowie Verfahren und Vorrichtung zur Herstellung derselben
DE502006009351D1 (de) Feinteiliges azopigment und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1845978

Country of ref document: EP